Author:
Hamasaki Toshimitsu,Asakura Koko,Evans Scott R.,Ochiai Toshimitsu
Reference9 articles.
1. Allen SJ, Wareham K, Bradley C, Harris W, Dhar A, Brown H, Foden A, Cheung WY, Gravenor MB, Plummer S, Phillips CJ, Mack D (2012) A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis 12:108
2. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D (2013) Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382:1249–1257
3. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, Evans SR, Sozu T (2014) Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med 33:2897–2913
4. Asakura K, Hamasaki T, Evans SR, Sugimoto T, Sozu T (2015) Sample size determination in group-sequential clinical trials with two co-primary endpoints. In: Chen Z, Liu A, Qu Y, Tang L, Ting N, Tsong Y (eds) Applied statistics in bio-medicine and clinical trial design (Chap. 14). Springer International Publishing, Cham, pp 235–262
5. Cui L, Hung HMJ, Wang SJ (1999) Modification of sample size in group sequential clinical trials. Biometrics 55:853–857